SB 190, the Pharmaceutical Transparency Act, creates a new independent state board to review high-cost prescription drug products and recommend ways to improve affordability for Pennsylvania residents, public agencies, health plans, providers, employers, and pharmacies. The board would be composed of seven members appointed by legislative leaders and the Governor, with expertise in health care economics or clinical medicine, and would operate with public meetings, public comment, disclosure rules, and conflict-of-interest restrictions designed to limit industry influence.
The bill requires manufacturers of certain high-cost drugs to submit detailed information to the board, including research and development costs, manufacturing and distribution costs, marketing and advertising expenses, profits, rebates, patient assistance programs, and payments or incentives to providers. The board would analyze this information, publish reports while protecting trade secrets, and issue annual and periodic studies on drug pricing trends, supply chain effects, pharmacy benefit managers, generic drug markets, and the relationship between drug prices and insurance or Medicaid costs. The act also establishes a dedicated fund to finance the board through assessments on manufacturers based on their share of prescription drug sales in Pennsylvania, and it authorizes the board to impose a $20,000-per-day-per-drug penalty for noncompliance.
In practical terms, the bill would add a new layer of state oversight over pharmaceutical pricing and reporting, affecting drug manufacturers most directly, but also potentially influencing insurers, pharmacy benefit managers, health care providers, pharmacies, employers, and state and local government purchasers. It would not directly set drug prices, but it would require extensive disclosure and create a state mechanism for identifying drugs that create affordability burdens and for recommending policy responses. The bill would take effect 60 days after enactment.
There is no recorded committee transcript or vote history provided, so no formal floor or committee sentiment can be measured from the available record. Based on the bill’s sponsors and structure, the measure appears aimed at addressing prescription drug affordability and transparency, suggesting support from lawmakers concerned about high drug costs. At the same time, the bill’s detailed reporting requirements, public disclosure provisions, and manufacturer-funded assessment system indicate likely concern from the pharmaceutical industry about compliance burdens, proprietary information, and the new penalty authority.
The main points of contention are likely to be the scope of required disclosures, the threshold for which drugs are covered, the board’s authority to access and publish pricing information, and whether the assessment and penalty structure unfairly targets manufacturers. Another likely issue is the balance between transparency and protection of trade secrets, since the bill requires public reporting while also allowing closed sessions and trade-secret protections. The conflict-of-interest rules and exclusion of industry-affiliated board members also suggest an effort to address concerns about bias, but those same restrictions may be viewed as limiting stakeholder participation.
SB 190 would create new statutory duties for prescription drug manufacturers to report extensive pricing, cost, rebate, profit, and assistance-program information to a newly established Pharmaceutical Transparency Review Board. It would also establish a new state fund in the Treasury, financed by manufacturer assessments, to support the board and implementation costs, and it would authorize the board to adopt regulations, contract with third parties, and impose civil-style penalties for noncompliance. The bill would primarily affect pharmaceutical manufacturers, but its reporting and analysis framework could also affect insurers, pharmacy benefit managers, providers, pharmacies, employers, and public purchasers through downstream policy recommendations and public reporting.
No committee discussion or vote record is available in the provided materials, so there is no documented legislative sentiment to summarize from debate or roll call. The bill’s introduction by multiple Democratic senators and its focus on affordability and transparency suggest a policy goal of lowering prescription drug costs and increasing public oversight. The absence of recorded opposition in the materials does not indicate consensus, but the bill’s design implies a reform-oriented approach that would likely be viewed favorably by consumer and health-cost advocates and more cautiously by industry stakeholders.
The likely areas of contention are the breadth of the reporting mandate, the requirement that manufacturers disclose sensitive financial and commercial information, and the board’s authority to determine when a drug creates an affordability burden. Pharmaceutical manufacturers may object to the assessment funding model, the $20,000-per-day-per-drug penalty, and the risk that proprietary information could be exposed despite trade-secret protections. Other stakeholders may debate whether the bill sufficiently accounts for the roles of pharmacy benefit managers, insurers, and the broader supply chain, or whether it places too much responsibility on manufacturers alone.